JPH05503710A - アルファー―2―アドレナリン作動薬及び成長ホルモン放出ペプチドによる肥満症の治療 - Google Patents
アルファー―2―アドレナリン作動薬及び成長ホルモン放出ペプチドによる肥満症の治療Info
- Publication number
- JPH05503710A JPH05503710A JP3514346A JP51434691A JPH05503710A JP H05503710 A JPH05503710 A JP H05503710A JP 3514346 A JP3514346 A JP 3514346A JP 51434691 A JP51434691 A JP 51434691A JP H05503710 A JPH05503710 A JP H05503710A
- Authority
- JP
- Japan
- Prior art keywords
- growth hormone
- grf1
- alpha
- secretion
- clonidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100033367 Appetite-regulating hormone Human genes 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims description 15
- 239000000048 adrenergic agonist Substances 0.000 title claims description 14
- 208000008589 Obesity Diseases 0.000 title claims description 10
- 235000020824 obesity Nutrition 0.000 title claims description 10
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 title claims description 8
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960002896 clonidine Drugs 0.000 claims abstract description 22
- 102000018997 Growth Hormone Human genes 0.000 claims abstract description 19
- 108010051696 Growth Hormone Proteins 0.000 claims abstract description 19
- 239000000122 growth hormone Substances 0.000 claims abstract description 19
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims abstract description 7
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims abstract 5
- -1 GHRH Chemical compound 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 230000028327 secretion Effects 0.000 claims description 11
- 239000005556 hormone Substances 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 4
- 101800000736 Growth hormone-releasing factor Proteins 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims 2
- 235000017491 Bambusa tulda Nutrition 0.000 claims 2
- 241001330002 Bambuseae Species 0.000 claims 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims 2
- 239000011425 bamboo Substances 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 230000004720 fertilization Effects 0.000 claims 1
- 235000020845 low-calorie diet Nutrition 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 102100022831 Somatoliberin Human genes 0.000 abstract description 18
- 101710142969 Somatoliberin Proteins 0.000 abstract description 18
- 230000004044 response Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 5
- 102400001370 Galanin Human genes 0.000 description 4
- 101800002068 Galanin Proteins 0.000 description 4
- 102000005157 Somatostatin Human genes 0.000 description 4
- 108010056088 Somatostatin Proteins 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 4
- 229960000553 somatostatin Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000064 cholinergic agonist Substances 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010053759 Growth retardation Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 241000252185 Cobitidae Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000219112 Cucumis Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 125000002698 D-tryptophano group Chemical group C(=O)(O)[C@@H](CC1=CNC2=CC=CC=C12)N* 0.000 description 1
- 101100422538 Escherichia coli sat-2 gene Proteins 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 210000004258 portal system Anatomy 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002099 somatostatinotropic effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (18)
- 1.肥満患者における成長ホルモンの分泌を誘発せしめるため、該肥満患者に成 長ホルモン放出ペプチドと同時に、独立に、又は逐次に投与するための医薬品の 製造においてアルファ−−2−アドレナリン作動薬を利用する方法。
- 2.肥満患者における成長ホルモンの分泌を誘発せしめるため、該肥満患者にア ルファ−−2−アドレナリン作動薬と同時に、独立に、または逐次に投与するた めの医薬品の製造において成長ホルモン放出ペプチドを利用する方法。
- 3.肥満患者における改良ホルモンの分泌を誘発せしめるために該肥満患者に成 長ホルモン放出ペプチドと同時に、独立に、又は逐次にアルファ−−2−アドレ ナリン作動薬を有効量において投与することによる肥満症の治療のための医薬品 の製造においてアルファ−−2−アドレナリン作動薬を利用する方法。
- 4.肥満患者における成長ホルモンの分泌を誘発せしめるために該肥満患者にア ルファ−−2−アドレナリン作動薬と同時に、独立に、又は逐次に成長ホルモン 放出ペプチドを有効量において投与することによる肥満症の治療のための医薬品 の製造において成長ホルモン放出ペプチドを利用する方法。
- 5.先に記載の請求項のいづれか1項に記載の利用方法であって、前記のアルフ ァ−−2−アドレナリン作動薬がクロニジンである方法。
- 6.先に記載の請求項のいづれかに1項に記載の利用方法であって、前記の成長 ホルモン放出ペプチドがGRF1−44、GRF1−40、GRF1−37又は GRF1−29である利用方法。
- 7.前記の成長ホルモンが次式: AA1−His−AA3−Ala−Trp−D−Phe−Lys−NH2 〔式中;AA1はH又はAla、そしてAA3はD−Trp又はD−β−Nal である〕である、請求項1〜5のいづれか1項に記載の利用方法。
- 8.肥満患者における成長ホルモンの分泌を誘発せしめるために、該患者に同時 に、独立に、又は逐次に投与するためのアドレナリン作動薬及び成長ホルモン放 出ペプチドを含む薬学キット。
- 9.肥満患者に有効量のアルファ−−2−アドレナリン作動薬及び成長ホルモン 放出ペプチドを同時に、独立に、又は逐次に投与せしめることを含んでなる、肥 満患者における成長ホルモンの分泌を誘発せしめる方法。
- 10.肥満症を治療するための方法であって、この症状を有す患者に、該患者に おける成長ホルモンの分泌を誘発せしめるために有効量においてアルファ−−2 −アドレナリン作動薬を成長ホルモン放出ペプチドと同時に、独立に、又は逐次 に投与せしめることを含んで成る方法。
- 11.前記のアルファ−−2−アドレナリン作動薬がクロニジンである、請求項 9又は10に記載の方法。
- 12.前記のクロニジンを、前記の成長ホルモン放出ペプチドの0〜約120分 前に投与する、請求項9に記載の方法。
- 13.前記の成長ホルモン放出ペプチドがGRF1−44、GRF1−40、G RF1−37又はGRF1−29である、請求項9〜12のいづれか1項に記載 の方法。
- 14.前記の成長ホルモン放出ペプチドが次式;AA1−His−AA3−Al a−Trp−D−Phe−Lys−NH2 〔式中;AA1はH又はAla、そしてAA3はD−Trp又はD−β−NaI である〕を有する、請求項9〜12のいづれか1項に記載の方法。
- 15.前記のクロニジンを約100〜約200マイクログラム/m2の量におい て投与する、請求項1〜14のいづれか1項に記載の方法。
- 16.前記のクロニジンを約150マイクログラム/m2の量において投与する 、請求項15に記載の方法。
- 17.前記の成長ホルモン放出ペプチドを竹1μg/kgの静脈内投与又は約1 0μg/kgの皮下投与の量において投与する、請求項9〜16のいづれか1項 に記載の方法。
- 18.前記の患者を低カロリーダイエットにかけることを更に含んで成る、請求 項9〜17のいづれか1項に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US580,686 | 1990-09-10 | ||
US07/580,686 US5120713A (en) | 1990-09-10 | 1990-09-10 | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05503710A true JPH05503710A (ja) | 1993-06-17 |
JP3255289B2 JP3255289B2 (ja) | 2002-02-12 |
Family
ID=24322121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51434691A Expired - Fee Related JP3255289B2 (ja) | 1990-09-10 | 1991-09-06 | アルファー―2―アドレナリン作動薬及び成長ホルモン放出ペプチドによる肥満症の治療 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5120713A (ja) |
EP (1) | EP0500847B1 (ja) |
JP (1) | JP3255289B2 (ja) |
AT (1) | ATE131063T1 (ja) |
AU (1) | AU650048B2 (ja) |
CA (1) | CA2072624C (ja) |
DE (1) | DE69115247T2 (ja) |
DK (1) | DK0500847T3 (ja) |
ES (1) | ES2080331T3 (ja) |
GR (1) | GR3018922T3 (ja) |
WO (1) | WO1992004040A1 (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5428013A (en) * | 1991-01-04 | 1995-06-27 | Mugica; Jesus D. | Differential diagnosis and treatment of the states of growth hormone insufficiency (or deficiency) with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
DE4325491A1 (de) * | 1993-07-29 | 1995-02-02 | Boehringer Ingelheim Kg | Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels |
US7077822B1 (en) | 1994-02-09 | 2006-07-18 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
US6129685A (en) * | 1994-02-09 | 2000-10-10 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
US5605886A (en) * | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
US6696063B1 (en) * | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
US6231594B1 (en) | 1999-08-11 | 2001-05-15 | Radiant Medical, Inc. | Method of controlling body temperature while reducing shivering |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
DK1363668T3 (da) * | 2001-01-26 | 2007-11-05 | Schering Corp | Kombinationer af galdesyrekompleksdanner(e) og sterolabsorptionsinhibitor(er) og behandling af vaskulære indikationer |
KR20080067717A (ko) * | 2001-01-26 | 2008-07-21 | 쉐링 코포레이션 | 스테롤 흡수 억제제와 혈액 조절제를 포함하는 혈관 질환의치료 또는 예방용 약제학적 조성물 |
CZ20032031A3 (cs) * | 2001-01-26 | 2003-12-17 | Schering Corporation | Farmaceutický prostředek |
CZ305202B6 (cs) * | 2001-01-26 | 2015-06-10 | Merck Sharp & Dohme Corp. | Farmaceutický prostředek |
US7071181B2 (en) * | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
AR034204A1 (es) * | 2001-01-26 | 2004-02-04 | Schering Corp | Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares |
AU2002247019C1 (en) * | 2001-01-26 | 2017-05-11 | Organon Llc | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
US6582457B2 (en) * | 2001-02-15 | 2003-06-24 | Radiant Medical, Inc. | Method of controlling body temperature while reducing shivering |
ES2275007T3 (es) * | 2001-05-25 | 2007-06-01 | Schering Corporation | Uso de derivados de azetidinona sustitudos en el tratamiento de la enfermedad de alzeimer. |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
JP2005504091A (ja) * | 2001-09-21 | 2005-02-10 | シェーリング コーポレイション | ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置 |
US7056906B2 (en) * | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
HUP0401501A3 (en) * | 2001-09-21 | 2012-02-28 | Schering Corp | Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s) |
US20030119808A1 (en) * | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
EP1560579A1 (en) * | 2002-11-06 | 2005-08-10 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of autoimmune disorders |
US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
WO2004081002A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
EP1680189A2 (en) * | 2003-11-05 | 2006-07-19 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
WO2009043520A1 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
US8231891B2 (en) | 2009-07-31 | 2012-07-31 | Warsaw Orthopedic, Inc. | Implantable drug depot for weight control |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224316A (en) * | 1979-03-30 | 1980-09-23 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
IT1191611B (it) * | 1985-05-15 | 1988-03-23 | Eugenio E Muller | Formalazioni farmaceutiche per stimolare la liberazione di ormone somatotropo |
GB2206880B (en) * | 1987-07-16 | 1991-04-24 | Farmos Oy | Optical isomers of an imidazole derivative |
-
1990
- 1990-09-10 US US07/580,686 patent/US5120713A/en not_active Expired - Lifetime
-
1991
- 1991-09-06 AT AT91914999T patent/ATE131063T1/de not_active IP Right Cessation
- 1991-09-06 DK DK91914999.7T patent/DK0500847T3/da active
- 1991-09-06 AU AU84305/91A patent/AU650048B2/en not_active Ceased
- 1991-09-06 DE DE69115247T patent/DE69115247T2/de not_active Expired - Fee Related
- 1991-09-06 ES ES91914999T patent/ES2080331T3/es not_active Expired - Lifetime
- 1991-09-06 CA CA002072624A patent/CA2072624C/en not_active Expired - Fee Related
- 1991-09-06 EP EP91914999A patent/EP0500847B1/en not_active Expired - Lifetime
- 1991-09-06 WO PCT/EP1991/001692 patent/WO1992004040A1/en active IP Right Grant
- 1991-09-06 JP JP51434691A patent/JP3255289B2/ja not_active Expired - Fee Related
-
1996
- 1996-02-07 GR GR960400328T patent/GR3018922T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE131063T1 (de) | 1995-12-15 |
DE69115247D1 (de) | 1996-01-18 |
US5120713A (en) | 1992-06-09 |
DK0500847T3 (da) | 1996-01-08 |
EP0500847A1 (en) | 1992-09-02 |
JP3255289B2 (ja) | 2002-02-12 |
CA2072624A1 (en) | 1992-03-11 |
GR3018922T3 (en) | 1996-05-31 |
EP0500847B1 (en) | 1995-12-06 |
WO1992004040A1 (en) | 1992-03-19 |
DE69115247T2 (de) | 1996-07-25 |
CA2072624C (en) | 1999-03-23 |
ES2080331T3 (es) | 1996-02-01 |
AU650048B2 (en) | 1994-06-09 |
AU8430591A (en) | 1992-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05503710A (ja) | アルファー―2―アドレナリン作動薬及び成長ホルモン放出ペプチドによる肥満症の治療 | |
Metz et al. | Induction of defective insulin secretion and impaired glucose tolerance by clonidine Selective stimulation of metabolic alpha-adrenergic pathways | |
PAYNE | Studies on the fat-mobilizing factor of the anterior pituitary gland | |
Morley et al. | Amylin decreases food intake in mice | |
Jenkins et al. | The relative effectiveness of somatostatin and octreotide therapy in pancreatic disease | |
JP3819932B2 (ja) | グルタミン酸塩およびnmdaレセプターにおけるペプチド拮抗物質の使用方法 | |
US20060084597A2 (en) | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity | |
PT762890E (pt) | Tratamento de diabetes | |
JPH06510760A (ja) | 代謝障害および代謝の治療法 | |
AU2006341375A1 (en) | Amylin and amylin agonists for treating psychiatric diseases and disorders | |
Hadley et al. | Anabolic strategies in critical illness | |
JPH0780761B2 (ja) | 痛みのある疾患又はアレルギー性疾患の治療用組成物及び治療法 | |
JP2008516994A (ja) | 成長ホルモン分泌促進因子およびその使用 | |
JP2568286B2 (ja) | メラトニン又はその同族体を含有する代謝老化防止剤 | |
JP2872809B2 (ja) | モノシアロガングリオシドgm▲下1▼またはその誘導体を含有する,パーキンソン病の治療に適する医薬組成物 | |
Cannavò et al. | Results of a two-year treatment with slow release lanreotide in acromegaly | |
JP3105541B2 (ja) | 慢性肝疾患治療剤 | |
Nealon et al. | Role of cholecystokinin in canine pancreatic exocrine response to bombesin stimulation | |
Efendić et al. | Effect of somatostatin on basal and glucose induced insulin release in five patients with hyperinsulinaemia | |
Forsyth et al. | Role of oropharyngeal stimulation in cholecystokinin-induced satiety in the sham feeding rat | |
Robinson | Aspirin and the adrenal cortex | |
Menguy | Mechanism of inhibition of gastric secretion by fat in the intestine. | |
US4910215A (en) | Pharmaceutical formulations designed to stimulate the release of somatotropic hormone | |
DOWNEY et al. | Physiologic Changes Associated with Bed Rest and Major Body Injury | |
Gyr | Therapeutic application of gut hormones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071130 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081130 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081130 Year of fee payment: 7 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081130 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081130 Year of fee payment: 7 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091130 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |